| Description |
REQUEST FOR PROPOSAL RFP NO: JSIPL/RFP/2023/005
Request for Proposals (RFP)
Hiring of an agency to gather stakeholder perspectives on giving additional injectable vaccines in a single visit under Universal Immunization Programme (UIP)
RFP NO: JSI/RFP/2023/ 005
This RFP document includes the following parts:
PART A: Cover Page
PART B: Instructions for Bidders
PART C: Terms of Reference
Attachment A: General Terms and Conditions
Attachment B: Financial Proposal Template (Attached as Separate Excel File)
All proposals, inquiries, and correspondence pertaining to this solicitation are to be directed to the email ID: procurement@in.jsi.com
PART A: COVER PAGE
Issuance Date:
30th March 2023
Questions Due Date/Time:
8th April 2023 by 1800 Hrs., India
Response to query
10th April 2023 by 1800 Hrs., India
Proposal Due Date/Time:
17th April 2023 by 1800 Hrs., India
Background
John Snow India Private Limited (JSIPL) is a subsidiary of John Snow, Inc. (JSI), a health care consulting and research organization dedicated to improving the health of individuals and communities in the U.S. and around the world. JSI’s mission is to improve the health of underserved people and communities and to provide a place where people of passion and commitment can pursue this cause. For 35 years, Bostonbased JSI and its affiliates have provided high-quality technical and managerial assistance to public health programs worldwide. JSI has implemented projects in 106 countries, and currently operates from eight U.S. and 81 international offices, with more than 500 U.S.-based professionals and 1,600 host country staff. In India, JSIPL implements and manages several public health projects in the areas of maternal, child and new-born health; supply chain logistics; immunization; and HIV.
India’s Universal Immunization Programme (U.I.P.) is one of the largest in the world in terms of quantities of vaccines used, the number of beneficiaries, the number of immunization sessions organized, the geographical spread and diversity of areas covered. Starting in the mid-1980s, JSI has provided extensive consultation to national, state, and local public health initiatives in India. JSI’s comprehensive approach to health systems design and management has improved the quality and efficiency of care in India in the fields of maternal and child health, immunization, supply chain, HIV/AIDS, HMIS, sanitation and access to clean water, outbreak preparedness, and nutrition, at both the national and state levels.
Proposed Task Overview
The UIP has achieved several milestones in the last decade, including the introduction of vaccines against 11 Vaccine Preventable Diseases nationwide. However, with the introduction of these new vaccines, the number of injections at a single vaccination visit has also increased. This is in accordance with the universally endorsed practice of simultaneous administration of all recommended vaccines that ensures uptake, improves timeliness, provides protection at the earliest possible age, and maximizes efficient use of available health sector resources.
However, it is anticipated that adding an additional injectable vaccine (e.g. TCV) might lead to hesitancy and reluctance to its acceptance among caregivers. It may also result in a lack of confidence in administering multiple injections among vaccinators, resulting in non-adherence with vaccination schedules, thereby affecting vaccine coverage. Due to the paucity of scientific evidence on the impact of administering multiple injectable vaccines in a single visit, particularly in the context of India, the proposed study aims to understand the perception and attitude of stakeholders towards the introduction of an additional injectable vaccine within the existing UIP schedule.
JSI invites proposals from agencies/companies/consortium for conducting the following:
To assess the acceptability of the inclusion of an additional injectable vaccine under the National immunization schedule (NIS) among stakeholders.
To identify the determinants for the acceptability among all stakeholders on the inclusion of an additional injectable vaccine under the NIS.
To review and recommend a suite of interventions to improve the uptake of multiple injectable vaccines in a single visit under the NIS.
To understand the programmatic and economic implications of different approaches to provide multiple injectable vaccines in a single visit under the NIS.
Thus, the most effective approach for achieving the expected task is encouraged and the award will be made to the Offeror whose proposal suggests the best value to JSIPL considering technical and cost factors. Agencies w |